Podcasts about heart rhythm

In this episode, CardioNerds Dr. Colin Blumenthal, Dr. Kelly Arps, and Dr. Yong Hao Yeo are joined by electrophysiology expert Dr. Bradley Knight to discuss atrial fibrillation (AF) management in challenging clinical scenarios. We explore arrhythmias in patients with pre-excitation syndromes, particularly Wolff-Parkinson-White (WPW) syndrome, and strategies for rhythm control. We also discuss AF management in pregnancy, adult congenital heart disease, and patients with tachycardia-bradycardia (tach-brady) syndrome. This episode provides essential insights into nuanced decision-making for the care of patients with complex arrhythmia profiles. Audio editing by CardioNerds academy intern, Grace Qiu. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! PEARLS AF in WPW is a true emergency—AV nodal blocking agents can be deadly. In patients with WPW syndrome, AF can rapidly conduct through the accessory pathway, risking ventricular fibrillation and sudden death. Avoid AV nodal blockers like beta-blockers and calcium channel blockers. Catheter ablation is the first-line rhythm control strategy in WPW. Catheter ablation carries a Class I recommendation and offers >90% success. If antiarrhythmic drugs are needed, sodium channel blockers like flecainide or propafenone are preferred in patients without structural heart disease. In pregnancy, protecting the mother is protecting the fetus. An unstable mother means an unstable fetus. Rate control is the first step in AF with rapid ventricular responses and electrical cardioversion is safe when needed. Multidisciplinary care is essential. AF in congenital heart disease is often outside the pulmonary veins. Surgical scars and chamber remodeling in ACHD patients often lead to AF from non-pulmonary vein foci. Electrogram-based mapping and targeted ablation strategies are essential to increase success rate of durable rhythm control. Tachy-brady syndrome may require pacing to unlock therapy. AF may cause atrial myopathy and sinus node dysfunction. These patients often require permanent pacing to allow safe use of rate-controlling medications like beta-blockers and to prevent syncope or chronotropic incompetence. Notes: Notes drafted by Dr. Yong Hao Yeo Why is atrial tachycardia in patients with WPW syndrome dangerous? Patients with WPW commonly present with supraventricular tachycardia (SVT) due to atrioventricular reentrant circuits, either orthodromic or antidromic. This SVT can degenerate into AF. In the absence of AV nodal as the governor between the atrium and ventricles, the accessory pathway may conduct impulses rapidly and frequently. This can lead to dangerously high ventricular rates, predisposing patients to ventricular fibrillation and sudden cardiac arrest. What are some strategies for rhythm control in patients with WPW and atrial tachycardia? Catheter ablation is the first-line therapy (Class I recommendation), with a success rate of over 90%. Ablation reduces the risk of sudden cardiac arrest, though some patients may remain prone to AF. If ablation is not feasible/ contraindicated, sodium channel blockers such as flecainide and propafenone are good options in patients without ischemia or structural heart disease (Class IIa recommendation). Amiodarone should be avoided because it has a long half-life, can accumulate in the system, and may delay definitive treatment with catheter ablation. AV nodal blocking agents like beta blockers and calcium channel blockers should be avoided, as they are less effective at controlling ventricular rate in WPW and can increase conduction over the accessory pathway. These agents can also exacerbate the risk of rapid ventricular rates during AF and worsen left ventricular function. What are some special considerations in managing AF in pregnant patients? The primary goal in managing cardiovascular disease during pregnancy is to protect the mother, as fetal outcomes depend on maternal well-being. Therefore, while caution is necessary, we should avoid undertreating pregnant patients with AF. In cases of AF with rapid ventricular response (RVR), rate control is usually the first-line strategy, with beta blockers preferred over digoxin or non-dihydropyridine calcium channel blockers. It is then reasonable to initially observe for spontaneous conversion in stable patients. Antiarrhythmic drugs (AADs) are generally avoided during the first trimester, but clinical judgment on a case-by-case basis is essential. Evidence for the safety of AADs in pregnancy is limited, often derived from their use in other conditions such as fetal SVT. Flecainide and sotalol are reasonable options for rhythm control (Class IIa recommendation). Electrical cardioversion is considered safe in pregnancy and should be utilized when indicated (Do not forget!). There is no pregnancy-specific thromboembolic risk stratification tool. CHA₂DS₂-VASc scoring and the presence of risk factors like mitral stenosis can help guide anticoagulation decisions, though the magnitude of thromboembolic risk during pregnancy remains unclear. Rate control agents are typically continued during delivery due to the increased physiologic stress of labor and delivery. Multidisciplinary care is crucial and should involve obstetrics, maternal-fetal medicine, cardiology, and electrophysiology specialists. What are some key considerations for AF management in patients with adult congenital heart disease (ACHD)? Patients with repaired congenital heart disease are at increased risk for arrhythmias due to two main factors: surgical scars that create arrhythmogenic foci and mechanical remodeling of the atria or ventricles resulting from the underlying disease. In these patients with structural heart disease, sodium channel blockers may not be ideal antiarrhythmic options. When selecting an antiarrhythmic drug, clinicians must consider the nature of structural or surgical impairments, such as right bundle branch block or prolonged QT interval. It is also essential to assess renal and hepatic function (often impaired in patients with ACHD) to ensure appropriate metabolism and clearance of antiarrhythmic medications. Electrogram-based ablation strategies (those leveraging artificial intelligence are developing!) may help identify effective ablation targets, which are often outside the pulmonary veins in patients with ACHD. These individualized approaches can improve ablation success rates in this complex patient population. What makes tachycardia-bradycardia (tach-brady) syndrome a unique challenge in arrhythmia management? Patients who present with both AF and bradycardia, especially with syncope, require a thoughtful diagnostic approach to identify the underlying rhythm disturbance. Extended cardiac monitoring, including event monitors or implantable loop recorders, can help capture intermittent arrhythmias and correlate them with symptoms. AF may lead to atrial myopathy, and since the sinus node resides within the atrium, this can result in sinus node dysfunction—a hallmark of tachy-brady syndrome. Following spontaneous conversion from AF to sinus rhythm, sinus node dysfunction may persist, leading to prolonged pauses or chronotropic incompetence. Management becomes more complex when beta-blockers are needed for AF with RVR, as they can exacerbate bradycardia. Permanent pacemaker implantation is often the next step to consider. Permanent pacemaker implantation is often considered to facilitate safe rate control in these cases. In younger patients, aggressive AF burden reduction may prevent atrial remodeling and the development of true atrial myopathy, potentially avoiding pacemaker implantation. References Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;149(1). doi:https://doi.org/10.1161/CIR.0000000000001193 ‌ Van IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36). doi:https://doi.org/10.1093/eurheartj/ehae176 ‌ Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. Published online May 1, 2023. doi:https://doi.org/10.1016/j.hrthm.2023.05.017 ‌ Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary. Journal of the American College of Cardiology. 2019;73(12):1494-1563. doi:https://doi.org/10.1016/j.jacc.2018.08.1028 ‌

This April 2026 Heart Rhythm Journal publication reports a sub-analysis of the CHAMPION-AF trial evaluating left atrial appendage closure (LAAC) versus oral anticoagulation in patients with atrial fibrillation who previously underwent catheter ablation. The analysis demonstrated that LAAC with the WATCHMAN FLX device provided comparable protection against stroke, systemic embolism, and cardiovascular death when compared with NOAC therapy, while also reducing long-term non-procedural bleeding events. These findings support consideration of LAAC as an alternative stroke prevention strategy in selected post-ablation AF patients through individualized, shared decision-making. Digital Education Committee Member Danesh Kella, MBBS, FHRS discusses this article from the Heart Rhythm Journal that preceded the Heart Rhythm 2026 Late-Breaking Clinical Trial. He is joined in the conversation by Jason T. Jacobson, MD, FHRS, Ammar M. Killu, MBBS, and Gregory M. Marcus, MD, FHRS.   Learning Objectives Describe the rationale for left atrial appendage closure as an alternative to chronic oral anticoagulation in patients with atrial fibrillation after catheter ablation. Review the efficacy and safety outcomes from the CHAMPION-AF sub-analysis comparing LAAC and NOAC therapy in post-ablation AF patients.  Discuss patient selection considerations and the role of shared decision-making when choosing stroke prevention strategies following AF ablation.    Podcast Contributors Danesh Kella, MBBS, FHRS Jason T. Jacobson, MD, FHRS Ammar M. Killu, MBBS Gregory M. Marcus, MD, FHRS    Host and Contributor Disclosure(s): J.T. Jacobson •Board/Advisory Committee Membership: Abbott Medical •Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, Vektor Medical, Inc. •Research: CardioFocus, Inc., Johnson and Johnson •Stocks, Privately Held: Atlas 5D D. Kella •Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, MBW Spectrum A. Killu •Board/Advisory Committee Membership: Boston Scientific •Honoraria/Speaking/Teaching/Consulting: AtriCure, Inc., Abbott, Biosense Webster, Inc., Siemans Healthineers •Research: Boston Scientific, Access Point Technologies G.M. Marcus •Honoraria/Speaking/Teaching/Consulting: InCarda Therapeutics •Research: NIH, PCORI, TRDRP •Stocks, Publicly Traded: InCarda Therapeutics  

This late-breaking sub-analysis from the CHAMPION-AF trial evaluated outcomes of left atrial appendage closure (LAAC) with the WATCHMAN FLX device versus oral anticoagulation in patients with atrial fibrillation who had previously undergone catheter ablation. Investigators found that LAAC provided similar protection against stroke, cardiovascular death, and systemic embolism compared with non-vitamin K oral anticoagulants (NOACs), while significantly reducing non-procedural bleeding events, regardless of prior ablation status. These findings suggest LAAC may be a viable alternative to long-term anticoagulation in select post-ablation AF patients through a shared decision-making approach. Join Digital Education Committee member Sandeep A. Saha, MD, MS, FHRS and his colleagues Scott C. Brancato, MD, FHRS and Rakesh Gopinathannair, MBA, MD, FHRS for this late-breaking coverage from Heart Rhythm 2026 in Chicago!   Learning Objectives Review the rationale for left atrial appendage closure as an alternative to long-term oral anticoagulation in patients with atrial fibrillation following catheter ablation. Analyze the CHAMPION-AF sub-analysis outcomes comparing LAAC and NOAC therapy with respect to stroke prevention, cardiovascular outcomes, and bleeding risk. Discuss how these findings may influence patient selection and shared decision-making for stroke prevention strategies in post-ablation atrial fibrillation care.    Podcast Contributors Sandeep A. Saha, MD, MS, FHRS Scott C. Brancato, MD, FHRS Rakesh Gopinathannair, MBA, MD, FHRS    Host and Contributor Disclosure(s): S. Brancato Nothing to disclose. R. Gopinathannair Board/Advisory Committee Membership: Heart Rhythm Society, AltaThera Pharmaceuticals Honoraria/Speaking/Teaching/Consulting: Abbott, Johnson and Johnson, Boston Scientific, Sanofi S. Saha Board/Advisory Committee Membership: Medtronic Honoraria/Speaking/Teaching/Consulting: Medtronic 

Episode Highlights With KatieWhy potassium is the #1 most underconsumed mineral todayHow potassium runs the sodium–potassium pump that powers the entire bodyWhy potassium is the mineral of calm electricity and inside-cell stabilityHow potassium affects insulin sensitivity, blood sugar, and metabolismThe role of potassium in heart rhythm, muscle relaxation, and digestionWhy low potassium mimics anxiety and hormone imbalanceHow potassium balances sodium and helps magnesium work betterThe best food sources ... fruits, roots, coconut water, beans, greensWhy low-carb and RO water increase potassium needsPractical ways to add more potassium without supplementsWhy potassium is essential for cell voltage, hormone signaling, and nervous system safetyResources MentionedLMNT electrolyte drinksBONCHARGEI like so many of their products - from their red light products to their sauna blankets. Red light has been so helpful for me during my recovery from Hashimoto's. To find out more, go to boncharge.com/wellnessmama and use code wellnessmama for 20% off!LMNTI talk often about the health benefits of salt and electrolytes and I am a big fan of LMNT canned drinks and packets. Go to drinklmnt.com/wellnessmana for a special offer.

This discussion reviews the late-breaking HRS 2026 study Total Fatal Adverse Events Following Atrial Fibrillation Ablation Reported in an FDA Mandatory Reporting System: A Matter of Concern? The TiFFANY Study, which examined fatal adverse event reports associated with atrial fibrillation ablation using data from the FDA MAUDE database. Faculty discuss the incidence and mechanisms of rare but serious complications across ablation technologies, including pulsed field ablation and thermal energy sources, and explore the implications for procedural safety, post-market surveillance, and clinical decision-making in AF ablation. Join host Melissa E. Middeldorp, MPH, PhD and her esteemed guests Christopher F. Liu, MD, FHRS and James Freeman, MD, MPH, Msci for this late-breaking coverage from Heart Rhythm 2026 in Chicago! Learning Objectives Describe the methodology and key findings of the TiFFANY study evaluating fatal adverse events following atrial fibrillation ablation. Compare reported safety signals and complication profiles among pulsed field ablation and traditional thermal ablation technologies. Assess the role and limitations of post-market adverse event databases in evaluating procedural safety and informing electrophysiology practice.  Podcast Contributors Melissa E. Middeldorp, MPH, PhD, FHRS Christopher F. Liu, MD, FHRS James Freeman, MD, MPH, Msci  Host and Contributor Disclosure(s): D.C. Raja Nothing to disclose. A. Deshmukh Honoraria/Speaking/Teaching/Consulting: GE Healthcare, Biotronik, Medtronic, Biosense Webster Research: AltaThera Pharmaceuticals P. Lim Nothing to disclose.  

Welcome to the latest episode of late-breaker coverage from Heart Rhythm 2026 in Chicago, with host Deep Chandh Raja, MBBS, MD, PhD, FHRS and his guests Paul Chun Yih Lim, MBBS, FHRS and Abhishek Deshmukh, MD. This discussion reviews the late-breaking HRS 2026 trial Safety and Performance of a Novel ICD Lead for Left Bundle Branch Area Pacing: Results from the ASCEND CSP Trial Arrhythmia, which evaluated a novel implantable cardioverter-defibrillator (ICD) lead designed specifically for left bundle branch area pacing (LBBAP). Faculty discuss the safety profile, implant success, pacing performance, and clinical implications of conduction system pacing using dedicated ICD technology, as well as how these findings may influence future device implantation strategies and physiologic pacing approaches in patients requiring defibrillator therapy.   Learning Objectives Assess the safety and procedural performance outcomes associated with left bundle branch area pacing in patients requiring ICD therapy.  Evaluate the potential role of conduction system pacing technologies in advancing physiologic pacing and device-based arrhythmia management. Describe the design and intended clinical application of the novel ICD lead evaluated in the ASCEND CSP trial.    Podcast Contributors Deep Chandh Raja, MBBS, MD, PhD, FHRS Paul Chun Yih Lim, MBBS, FHRS Abhishek Deshmukh, MD   Host and Contributor Disclosure(s): D.C. Raja Nothing to disclose. A. Deshmukh Honoraria/Speaking/Teaching/Consulting: GE Healthcare, Biotronik, Medtronic, Biosense Webster Research: AltaThera Pharmaceuticals P. Lim Nothing to disclose.

Join Digital Education Committee member Jason T. Jacobson, MD, FHRS, and his guests John L. Sapp, Jr., MD, FHRS and Kyoko Soejima, MD for this conversation at Heart Rhythm 2026 in Chicago. This discussion reviews the late-breaking clinical trial Ventricular Intramyocardial Navigation and Tachycardia Ablation Guided by Electrograms (VINTAGE): First-in-Human Experience with a Novel Therapy for Refractory Ventricular Arrhythmia, presented at HRS 2026 in Chicago. Faculty discuss the novel VINTAGE technique, which enables catheter-based navigation and ablation within the myocardial wall to target deep intramural ventricular arrhythmia substrates that are often inaccessible with conventional endocardial or epicardial approaches. The conversation highlights the potential clinical impact of this first-in-human experience, including procedural feasibility, mechanistic innovation, and future implications for the treatment of patients with refractory ventricular tachycardia and complex ventricular arrhythmias.   Learning Objectives Describe the VINTAGE intramyocardial navigation approach and its proposed role in the treatment of refractory ventricular arrhythmias.  Evaluate the clinical challenges associated with mapping and ablating deep intramural ventricular tachycardia substrates using conventional techniques.  Assess the potential implications of first-in-human feasibility and safety findings for future ventricular arrhythmia ablation strategies.    Podcast Contributors Jason T. Jacobson, MD, FHRS John L. Sapp, Jr., MD, FHRS Kyoko Soejima, MD   Host and Contributor Disclosure(s): J. Jacobson • Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, Vektor Medical Inc. • Stocks, Privately Held: Atlas 5D • Research: CardioFocus, Inc. • Membership on Advisory Committees: Abbott Medical, Johnson and Johnson J. Sapp • Honoraria/Speaking/Teaching/Consulting: Medtronic, Varian Medical Systems, Biosense Webster • Research: Abbott Medical, Biosense Webster K. Soejima • Honoraria/Speaking/Consulting: Medtronic Japan, Boston Scientific Japan, Abbott Medical, Abbott Japan, Boehringer Ingelheim, Daiichi Sankyo 

Welcome to the third in this week's series of Lead episodes covering late breaking clinical trials from Heart Rhythm 2026 in Chicago. Join host Michael Lloyd, MD, FHRS, and his guests Christopher Kowalewski, MD and Karin Benali, MD, PhD for this discussion. This first-in-human, prospective study presented at Heart Rhythm 2026 evaluated noninvasive proton beam cardiac radioablation for patients with refractory ventricular tachycardia who had failed prior ablation and medical therapy. In a small, high-risk cohort, proton therapy was feasible and demonstrated substantial reductions in VT burden (approximately 80%) with no significant treatment-related toxicity observed during follow-up. These early findings highlight proton beam radioablation as a promising, highly targeted, noninvasive treatment option, though larger studies are needed to confirm long-term safety and durability.   Learning Objectives: Describe the principles of cardiac radioablation and the advantages of proton beam therapy compared with photon-based approaches for treating ventricular tachycardia.  Evaluate early feasibility, safety, and efficacy outcomes of proton beam therapy in patients with refractory ventricular tachycardia.  Assess the potential role of noninvasive cardiac radioablation in the treatment algorithm for patients with drug- and ablation-refractory ventricular tachycardia.    Podcast Contributors Michael S. Lloyd, MD, FHRS Christopher Kowalewski, MD Karin Benali, MD, PhD   Host and Contributor Disclosure(s): M. Lloyd •Honoraria/Speaking/Teaching/Consulting: Medtronic •Membership on Advisory Committees: Boston Scientific K. Bemali Nothing to disclose. D. Chew Nothing to disclose.

Welcome to the second episode this week in our triple header of late breaking clinical trials coverage from Heart Rhythm 2026 in Chicago. Host Christopher C Cheung, MD, MPH, FHRS is joined by Mihail G. Chelu, MD, PhD, FHRS and Derek Chew, MD, MS, FHRS for a conversation in Chicago. The LEAP2 trial, a first-in-human chronic feasibility study presented at Heart Rhythm 2026, evaluated a novel leadless pacemaker designed for conduction system pacing to more closely replicate physiologic cardiac activation. Early results from this small cohort demonstrated high implantation success, reliable device performance, and effective pacing of the heart's native conduction pathways through short-term follow-up. These findings highlight the potential of leadless conduction system pacing as an innovative alternative to traditional pacing strategies, pending further long-term data.   Learning Objectives Describe the principles and clinical rationale for conduction system pacing and how it differs from traditional right ventricular pacing.  Evaluate early safety and performance outcomes of novel leadless pacemaker systems designed for physiologic pacing.  Assess the potential clinical implications and future role of leadless conduction system pacing technologies in patients requiring permanent pacing.   Podcast Contributors Christopher C Cheung, MD, MPH, FHRS Mihail G. Chelu, MD, PhD, FHRS Derek Chew, MD, MS, FHRS   C. Cheung •Honoraria/Speaking/Teaching/Consulting: Medtronic, Biotronik, Biosense Webster, Abbott M. Chelu •Honoraria/Speaking/Teaching/Consulting: Impulse Dynamics, USA •Research: Abbott, Impulse Dynamics USA, VDI Technologies, PCORI, NIH/NHLBI D. Chew •Research: Canadian Institute of Health Research, Heart and Stroke Foundation of Canada

Welcome to the first episode in this week's triple-header of late-breaking clinical trial coverage from Heart Rhythm 2026 in Chicago. In this episode Melissa E. Middeldorp, MPH, PhD from the Digital Education Committee sits down with David H. Birnie, MD and T. Jared Bunch, MD, FHRS to talk through this exciting late breaker. This late-breaking substudy of the ALONE-AF trial presented at Heart Rhythm 2026 evaluated whether discontinuing oral anticoagulation (OAC) after successful atrial fibrillation ablation impacts cognitive function in patients without long-term recurrence. The findings suggest that stopping OAC approximately one year post-ablation does not adversely affect cognitive outcomes, with cognitive scores improving similarly in both discontinuation and continuation groups among patients who remained arrhythmia-free. These results support the potential safety of OAC discontinuation in selected patients, while addressing an important gap in post-ablation management. Learning Objectives Understand the clinical rationale and current uncertainty surrounding continuation versus discontinuation of oral anticoagulation after successful AF ablation. Evaluate the impact of anticoagulation discontinuation on cognitive function in patients without recurrent atrial fibrillation. Apply emerging evidence from ALONE-AF and related studies to inform individualized decision-making on long-term anticoagulation management post-ablation.   Podcast Contributors Melissa E. Middeldorp, MPH, PhD David H. Birnie, MD T. Jared Bunch, MD, FHRS   Contributor Information: M. Middeldorp Nothing to disclose. D. Birnie Nothing to disclose.  T.J. Bunch • Honoraria/Speaking/Teaching/Consulting: Heart Rhythm Society, Pfizer  

KYW Newsradio's Rasa Kaye and Dr. Raffaele Corbisiero, a cardiac electrophysiologist at Deborah Heart and Lung Center continue their conversation about the future of heart rhythm care.

KYW Newsradio's Rasa Kaye explores the future of heart rhythm care with Dr. Raffaele Corbisiero, a cardiac electrophysiologist at Deborah Heart and Lung Center.

Magnesium powers over 3,000 body functions. Find out the best forms, when to take it, and why most people are deficient. #MagnesiumMatters #MineralDeficiency #SleepSupport

Regular energy drink use pushes your heart and blood vessels into a constant stress state that medications and fitness can't override while stimulants remain in your system Severe blood pressure spikes and dangerous heart rhythm events have occurred in people drinking energy drinks who appeared healthy and had no prior heart disease Energy drinks stack caffeine with other stimulants and added sugar, creating a combined strain that overwhelms normal cardiovascular control mechanisms Low cellular energy drives the urge to rely on stimulants, but energy drinks mask the problem rather than restoring real energy production Removing energy drinks and rebuilding cellular energy through food, movement, and daily structure helps your heart regain stability and lowers real cardiovascular risk

Contributor: Aaron Lessen, MD Educational Pearls: How do amiodarone and lidocaine work on the heart? Amiodarone Blocks potassium channels (Class III effect). Also blocks sodium and calcium channels. Additional noncompetitive beta-blocker effects. Stabilizes cardiac tissue, slows heart rate, and suppresses both atrial and ventricular arrhythmias. Lidocaine Blocks fast sodium channels in ventricular tissue (Class Ib). Shortens the action potential in ventricular myocardium, especially in ischemic tissue. Suppresses abnormal automaticity in damaged/irritable myocardium. Which one should you pick for a patient in vtach/vfib cardiac arrest? The current guidelines recommend amiodarone for shock-refractory cases but this is based on randomized trials showing better arrhythmia termination and short-term outcomes, but not long-term survival benefits. Two recent studies suggest that lidocaine might actually be preferable. A 2023 paper published in Chest Performed a large retrospective cohort study for treating in-hospital VT/VF cardiac arrest. Among more than 14,000 patients, lidocaine was associated with higher rates of ROSC, 24-hour survival, survival to discharge, and favorable neurologic outcomes. These results held after adjusting for covariates and using propensity score methods. Overall, lidocaine outperformed amiodarone across all major clinical outcomes in this population. A 2025 paper published in Resuscitation Performed a target trial emulation in adults with out-of-hospital shockable cardiac arrest. After propensity score matching in more than 23,000 eligible cases, lidocaine was associated with higher odds of prehospital ROSC, fewer post-drug defibrillations, and greater survival to hospital discharge. These advantages were consistent across matched patient pairs. Dose for lidocaine is an initial 1-1.5 mg/kg IV bolus, followed by additional boluses of 0.5-0.75 mg/kg every 5-10 minutes up to a total of 3 mg/kg if needed. Dose for amiodarone is a 300 mg bolus followed by an additional 150 mg bolus if needed. References Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018 Oct;15(10):e190-e252. doi: 10.1016/j.hrthm.2017.10.035. Epub 2017 Oct 30. Erratum in: Heart Rhythm. 2018 Nov;15(11):e278-e281. doi: 10.1016/j.hrthm.2018.09.026. PMID: 29097320. Smida T, Crowe R, Price BS, Scheidler J, Martin PS, Shukis M, Bardes J. A retrospective 'target trial emulation' comparing amiodarone and lidocaine for adult out-of-hospital cardiac arrest resuscitation. Resuscitation. 2025 Mar;208:110515. doi: 10.1016/j.resuscitation.2025.110515. Epub 2025 Jan 23. PMID: 39863130; PMCID: PMC11908894. Wagner D, Kronick SL, Nawer H, Cranford JA, Bradley SM, Neumar RW. Comparative Effectiveness of Amiodarone and Lidocaine for the Treatment of In-Hospital Cardiac Arrest. Chest. 2023 May;163(5):1109-1119. doi: 10.1016/j.chest.2022.10.024. Epub 2022 Nov 2. PMID: 36332663. Summarized by Jeffrey Olson, MS4 | Edited by Jeffrey Olson and Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/

The FDA belatedly liberates women's hormone replacement; Beta-blockers now deemed passé for routine heart attack aftercare; After most breast cancer surgery, adjuvant radiation brings no survival benefits; Can you drink caffeinated coffee if you have atrial fibrillation? Ignore frequent falls without attention to balance and stability training at your peril; Is it reasonable to contemplate a knee replacement surgery at 88? 

Heart Rhythm Meditation’s Miraculous Transformations When theHeartbeat is Synchronized with the Breath. Extraordinary things happen when you sync your heartbeat and your breath! Watch https://www.transformationtalkradio.com/watch.html

Heart Rhythm Meditation’s Miraculous Transformations When theHeartbeat is Synchronized with the Breath. Extraordinary things happen when you sync your heartbeat and your breath! Watch https://www.transformationtalkradio.com/watch.html

Heart Rhythm Meditation’s Miraculous Transformations When theHeartbeat is Synchronized with the Breath. Extraordinary things happen when you sync your heartbeat and your breath! Watch https://www.transformationtalkradio.com/watch.html

Heart Rhythm Meditation’s Miraculous Transformations When theHeartbeat is Synchronized with the Breath. Extraordinary things happen when you sync your heartbeat and your breath! Watch https://www.transformationtalkradio.com/watch.html

Heart Rhythm Meditation's Miraculous Transformations When theHeartbeat is Synchronized with the Breath.  Extraordinary things happen when you sync your heartbeat and your breath! Watch https://www.transformationtalkradio.com/watch.html 

Heart Rhythm Meditation's Miraculous Transformations When theHeartbeat is Synchronized with the Breath.  Extraordinary things happen when you sync your heartbeat and your breath! Watch https://www.transformationtalkradio.com/watch.html 

Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Sotatercept HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/ PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944 II Acoramidis and ATTR Cardiomyopathy ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=true ATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013 Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689 III Pacing After TAVI Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028 PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019 Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030 Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Please join HRS Digital Education Committee Vice-Chair, Tina Baykaner, MD, MPH, of Stanford University, as she is joined by Heart Rhythm Society President Mina K. Chung, MD, FHRS, of the Cleveland Clinic, and Konstantinos C. Siontis, MD, FHRS of the May Clinic. The three met up in Altanta at HRX 2025 for this stimulating coversation. This study evaluated whether artificial intelligence applied to single-lead ambulatory ECGs could predict imminent sustained ventricular arrhythmias. Using deep learning models, the researchers demonstrated that AI could identify subtle ECG features preceding arrhythmic events, enabling accurate short-term risk prediction. The findings suggest a potential role for AI-enhanced ECG monitoring to improve early detection and prevention of life-threatening ventricular arrhythmias. To view bonus video recorded LIVE at HRX 2025 in Atlanta, view this episode on Heart Rhythm 365 or the HRX Innovation Hub! Article Authors Laurent Fiorina ∙ Tanner Carbonati∙ Kumar Narayanan ∙ Jia Li ∙ Christine Henry ∙ Jagmeet Singh ∙ Eloi Marijon Read the Article: https://www.heartrhythmjournal.com/article/S1547-5271(23)02195-1/fulltext Podcast Contributors and Disclosures Tina Baykaner, MD, MPH | Stanford University Mina K. Chung, MD, FHRS | Cleveland Clinic Konstantinos C. Siontis, MD, FHRS | Mayo Clinic All relevant financial relationships have been mitigated. T. Baykaner:   •Honoraria/Speaking/Consulting: Volta Medical, Medtronic, Pacemate, Johnson and Johnson, Abbot Medical, Boston Scientific Research: NIH M. Chung: •Honoraria/Speaking/Consulting: University of Chicago, Cedars Sinai Medical Center, Asia Pacific Heart Rhythm Society, NIH, Baylor College of Medicine, Kansas City Heart Rhythm Symposium, American College of Cardiology, Geisinger Health Systems, ABIM, Academy for Continued Healthcare Learning, MediasphereMedical, Western AF Symposium, University of Minnesota, Stanford University, Canadian Heart Rhythm Society •Research: NIH, American Heart Association •Royalty Income: Elsevier, Wolters Kluver •Officer: American Heart Association K. Siontis: •Research: Anumana, Varian Medical Systems •Intellectual Property Right: Anumana •Speaking/Teaching/Consulting: EBAMedSA, AskBio

Puran and Susanna Bair of iamHeart school, authors Living from the Heart: A Guide to Heart Rhythm Meditation and Energize Your Heart in 4 Dimensions, meditation, health, women's health, mental health, destress, control emotions

With Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia, Vera Maslova, University Medical Center of Schleswig-Holstein, Kiel - Germany, Daniel Scherr Medical University of Graz, Austria, and Michal Farkowski, Ministry of Interior and Administration National Medical Institute, Warsaw, Poland. During this podcast Daniel Scherr, Michal Farkowski, Stefan Simovic and Vera Maslova will explore the newly published 2025 ESC-EHRA Atlas on Heart Rhythm Disorders, featured in EP Europace journal offering key insights into global arrhythmia care. 

In this episode, Susanna and Puran Bair talk about Heart Rhythm Meditation's Miraculous Transformations When the Heartbeat is Synchronized with the Breath.  The post 445: Susanna and Puran Bair – Heart Rhythm Meditation's Miraculous Transformations When the Heartbeat is Synchronized with the Breath appeared first on Your Sacred Purpose.

This late-breaking randomized trial, published online on April 26, 2025 in Heart Rhythm, demonstrated that using CT scan guidance for ventricular tachycardia (VT) ablation significantly shortens procedure time while maintaining a safety profile comparable to conventional methods. In essence, CT-guided ablation offers a faster, equally safe alternative for VT treatment. A discussion of the late breakers was recorded live in San Diego at Heart Rhythm 2025. https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02182-4/fulltext Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting: Zoll Medical, Abbott Medical, Vektor Medical Stocks, Privately Held: Atlas 5D Research: CardioFocus, Inc. Contributor Disclosure(s): T. Dickfield: Honoraria/Speaking/Consulting: Impulse Dynamics USA Stock Options, Privately Held: inHeart N. Trayanova: Honoraria/Speaking/Consulting: Medtronic Inc., Volta Medical, Catheter Precision, Mediasphere Medical, Medical Device Business Services Research: National Institutes of Health

Join us at Heart Rhythm 2025 for the discussion of this study. Between July 2014 and June 2023, researchers tracked 641 sudden cardiac arrest (SCA) incidents in U.S. athletes aged 11–29. Overall survival was 49%, rising to 57% during exercise, and reaching 70% in game/competition settings compared to 53% during practice. Survival rates improved significantly over the nine years, yet notable racial disparities persisted: Black athletes were 37% less likely, and athletes of other non-White races 31% less likely, to survive exertional SCAs than White athletes. The authors emphasize that while improvements in emergency preparedness (CPR/AED access) likely contributed to better outcomes, targeted efforts are needed to address equity and bolster response during practices and in under-resourced communities. https://www.hrsonline.org/education/TheLead https://www.sciencedirect.com/science/article/abs/pii/S0735109725053379 Host Disclosure(s): M. Middeldorp: Nothing to disclose. Contributor Disclosure(s): E. Chung: Nothing to disclose. R. Lampert: Nothing to disclose.

Join HRS Board Member Prashanthan Sanders, MBBS, PhD, FHRS (University of Adelaide) as he discusses this exciting paper, presented at Heart Rhythm 2025. He is joined in the Heart Rhythm Tv Studio in San Diego, California by Louise Segan, MBBS, MPH (Alfred Health), and Takanori Yamaguchi, MD, PhD (Saga University). This discussion took place on-site at Heart Rhythm 2025.   https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)01245-7/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): T. Yamaguchi: Honoraria/Speaking/Consulting: Abbott Japan, Biotronik, Boston Scientific, Abbott Medical, Japan Medtronic, Inc., Daiichi Sankyo, Novartis, Japan Lifeline, Nihon Kohden, Bayer Healthcare Pharmaceuticals Japan, Boehringer Ingelheim L. Segan: Nothing to disclose.

This week is Heart Rhythm Awareness Week, a national campaign focusing on educating the public about heart rhythm disorders, particularly atrial fibrillation. In Ireland, one in four deaths are caused by heart disease and stroke each year For more Prof. Mark Dayer, Head of Heart Failure and Consultant Cardiologist at the Mater Private in Dublin.

Die Themen in den Wissensnachrichten: +++ Bei Frauen und Männern reagiert das Herz nicht immer gleich auf Sport +++ Hunde sollten nach dem Behandeln gegen Flöhe und Zecken besser länger nicht schwimmen +++ Schnellste Glasfaser-Datenübertragung +++**********Weiterführende Quellen zu dieser Folge:Sex-specific performance of electrocardiographic criteria for left ventricular hypertrophy in elite athletes, Heart Rhythm (2025)Swimming emissions from dogs treated with spot-on fipronil or imidacloprid: Assessing the environmental risk, VetRecord, 23.05.2025National Institute of Information and Communications Technology (NICT), 29.05.2025Turning rough surfaces into non-line-of-sight cameras, Optica, (2025)An ethogram of facial behaviour in domestic horses: evolutionary perspectives on form and function, PeerJ, 28.05.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

This week Zorba and Karl look at a study showing ultraprocessed foods will increase your chance of an early death, and they look at research that found brisk walking pace plus time spent at this speed may lower risk of heart rhythm abnormalities. Plus, they share a delicious recipe for a Spring Salad with Goat Cheese.

This week Zorba and Karl look at a study showing ultraprocessed foods will increase your chance of an early death, and they look at research that found brisk walking pace plus time spent at this speed may lower risk of heart rhythm abnormalities. Plus, they share a delicious recipe for a Spring Salad with Goat Cheese.

Join host and Digital Education Chair Prashanthan Sanders, MBBS, PhD, FHRS, as he discusses this article from Nature with guests Anand N Ganesan, MBBS, PhD, and Tina Baykaner, MD, MPH. This trial was also presented as a late-breaking clinical trial at Heart Rhythm 2024.   https://www.hrsonline.org/education/TheLead https://www.nature.com/articles/s41591-025-03517-w   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): A. Ganesan: Honoraria/Speaking/Consulting: Biosense Webster, Inc. T. Baykaner: Honoraria/Speaking/Consulting: Medtronic, Pacemate, Volta Medical, iRhythm Technologies; Research: NIH   This episode is worth 0.25 ACE credits. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode99

In this episode, Dr. Greg welcomes health coach Loredana Morett, NBC-HWC, to explore the profound connections between the mind, heart, and body. Loredana shares her journey from practicing traditional medicine to embracing integrative health, as she and Dr. Greg discuss how heart-brain “coherence,” heart rate variability, and mindful practices like breathwork can foster true healing and well-being. They dive into recent research on the heart's “little brain,” a neural network that influences emotional and physical health, highlighting simple steps to help you align and strengthen your mind-body connection. If you're curious about subtle signs of balance within the body and looking for ways to deepen your wellness journey, this conversation offers both inspiration and practical insights. Episode Highlights: [00:02:00] Loredana's journey to health coaching [00:15:00] The science of heart-brain coherence and HRV [00:24:00] Practical tools for emotional resilience [00:30:00] Understanding the “little brain” in the heart Episode Resources: "Gut-Brain-Immune Axis and Health" Durack J, Lynch SV. "The gut microbiome: Relationships with disease and opportunities for therapy." J Exp Med. 2019; 216(1):20-40. https://rupress.org/jem/article/216/1/20/42456/The-gut-microbiome-Relationships-with-disease-and Cryan JF et al. "The Microbiota-Gut-Brain Axis." Physiol Rev. 2019; 99(4):1877-2013. https://journals.physiology.org/doi/full/10.1152/physrev.00018.2018 Dinan TG, Cryan JF. "Brain-Gut-Microbiota Axis and Mental Health." Psychosom Med. 2017; 79(8):920-926. https://pubmed.ncbi.nlm.nih.gov/28806201/ "Heart-Brain Coherence and Cardiac Nervous System" Armour JA, Ardell JL. "The role of intrinsic cardiac neurons in cardiac function in health and disease." J Cardiovasc Electrophysiol. 2017; 28(1):3-12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7712215/ Hou Y, Liu L. "The intrinsic cardiac nervous system and its relevance for arrhythmogenesis." Heart Rhythm. 2017; 14(1):189-195. Fedele L, Brand T. "The Intrinsic Cardiac Nervous System and Its Role in Cardiac Pacemaking and Conduction." J Cardiovasc Dev Dis. 2020; 7(4):54. https://pubmed.ncbi.nlm.nih.gov/19733814/ Giannino G et al. "The Intrinsic Cardiac Nervous System: From Pathophysiology to Therapeutic Implications." Biology (Basel). 2024; 13(2):105. https://www.mdpi.com/2308-3425/7/4/54 "Cardiac Coherence and Emotional Health" McCraty R, Zayas MA. "Cardiac coherence, self-regulation, autonomic stability, and psychosocial well-being." Front Psychol. 2014; 5:1090. https://www.mdpi.com/2079-7737/13/2/105 "Integrative and Patient-Centered Care" Maizes V, Rakel D, Niemiec C. "Integrative medicine and patient-centered care." EXPLORE. 2009; 5(5):277–289. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2014.01090/full Want to become a patient of Dr. Greg Functional Medicine? Head to https://vitaefm.com/get-started/ SUBSCRIBE for More Content! Follow for more The Daily Dose with Dr. Greg episodes coming soon! If you'd like to connect with Dr. Greg, reach out on social media at @drgreghealth on Facebook, Instagram, and TikTok for daily insights and updates!

Dr. Ryan Cooley's journey from a heart attack survivor to a pioneer in metabolic health is nothing short of transformative. After following conventional medical advice and still suffering a heart attack, Dr. Cooley began questioning the lipid hypothesis and delving into how diet and lifestyle can influence genetic predispositions. With a special focus on insulin resistance and cardiac health, he shares his insights and personal experiences, challenging the prevailing norms and shedding light on new approaches to preventing heart disease.In this episode, we dig into the complex relationship between insulin resistance, visceral fat, and cardiovascular diseases like atrial fibrillation. Dr. Cooley explains how fat accumulation around vital organs triggers inflammatory responses and arrhythmias, advocating for a focus on metabolic health over merely lowering LDL cholesterol levels. His personal and clinical observations provide a compelling argument for a more holistic approach to managing heart health, emphasizing the often-overlooked role of cardiac fat.We explore the nuances of reversing insulin resistance and the difficulties of diagnosing ectopic fat, often invisible from the outside. Dr. Cooley shares his transition from a vegan diet to a keto vegetarian and nearly carnivore diet, leading to improved lipid profiles and overall heart health. The discussion extends to the importance of satiety, specific medical tests, and the future of cardiometabolic care, including plans for a clinic centered on lifestyle interventions. Tune in to learn how these insights can pave the way for better preventive measures in heart disease management.Key Takeaways- Over 90% of arrhythmia patients show insulin resistance- Fat accumulation around heart tissue directly impacts heart rhythm- Traditional treatments often miss the metabolic root cause- Dietary changes can improve orSend Dr. Ovadia a Text Message. (If you want a response, include your contact information.) Joburg MeatsKeto/Carnivore-friendly meat snacks. Tasty+Clean. 4 ingredients. Use code “iFixHearts” to save 15%. Chances are, you wouldn't be listening to this podcast if you didn't need to change your life and get healthier. So take action right now. Book a call with Dr. Ovadia's team. One small step in the right direction is all it takes to get started. How to connect with Stay Off My Operating Table:Twitter: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Learn more about Dr. Ovadia's personalized health coaching Get Dr. Ovadia's book Stay Off My Operating Table on Amazon. Take Dr. Ovadia's metabolic health quiz: iFixHearts visit Dr. Ovadia's website: Ovadia Heart Health visit Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

The Lead is a journal review podcast designed to keep listeners up to date and informed on the latest publications and hottest topics in electrophysiology. The Lead's session at Heart Rhythm 2024 includes three discussions, covering Transvenous Extraction of Conduction System Pacing Leads: An International Multicenter (TECSPAM) study and Safety, Efficacy, and Reliability Evaluation of a Novel Small-Diameter Defibrillation Lead: Global LEADR Pivotal Trial Results from the May 2024 issue of Heart Rhythm Journal, as well as Tachycardia therapy and Endpoint Results of the First Modular, Intra-body, Communicating Subcutaneous Defibrillator-Leadless Pacemaker System: MODULAR ATP Interim Cohort from the May 2024 issue of the New England Journal of Medicine. Join us for a lively and informative discussion!   https://www.hrsonline.org/education/TheLead   Host Disclosure(s): C. Cheung: Research: Abbott, Speaking/Teaching: Biosense Webster, Abbott, Biotronik D. Kella: Speakering, Teaching, and Consulting: Zoll Medical Corporation D. Varghese: Nothing to disclose   Contributor Disclosure(s): C. Rinaldi: Research: Abbott, Medtronic, Boston Scientific, LivaNova, Membership on Advisory Committees: EBR Systems, Speaking and Teaching: Spectranetics Corporation M. Leal: Speaking and Teaching: Sanofi, Research: Medtronic R. Pathak: Nothing to disclose. M. Chelu: Research: Impulse Dynamics USA, Abbott, PCORI, NIH/NHLBI, Speaking and Teaching: Impulse Synamics USA A.  Amin: Speaking, Teaching, and Consulting: Medtronic, Boston Scientific, Philips E. Zeitler: Research: Sanofi, Bionsense Webster, Inc., Speaking, Teaching, and Consulting: Biosense Webster, Inc., Boston Scientific, Element Science, Inc., Membership on Advisory Committees: Medtronic

On this week's episode of Flourish or Fold, I recently had the privilege of sitting down with Nick Sullivan, a seasoned technologist with over two decades of experience in Silicon Valley. Nick, the former CEO of the cryptocurrency company Heart Rhythm, joined me to share his profound insights on heart-led leadership and the delicate balance between humanity and technology. Nick shares his journey of leading with heart and facing setbacks, including the company's closure due to market crises. He discusses the importance of trust, resilience, and emotional recovery, as well as his pivot towards the AI industry. The episode delves into themes of surrender, manifestation, and the power of resilience, concluding with a promotion for a resilience leadership course.The Rise and Fall of Heart Rhythm: Nick's journey as an entrepreneur and CEO is nothing short of a rollercoaster ride. He led Heart Rhythm with a vision to channel capital into social impact projects, but the path was fraught with unforeseen challenges. The Terra Luna crisis dealt a heavy blow to the company, and the shockwaves from FTX's explosion further destabilized the cryptocurrency ecosystem. Despite his relentless drive to push through adversity, Nick faced the heart-wrenching decision to close the doors of Heart Rhythm.The Essence of Trust and Resilience: In our conversation, Nick opened up about the role of trust and resilience during these tumultuous times. He underscored the importance of psychological safety, love, and empathy in leadership. It's not just about steering a company through the storm; it's about nurturing a culture where humanity thrives alongside technology.Healing and Finding a New Direction: The emotional investment Nick poured into Heart Rhythm was immense, and the setbacks took a significant toll. He spoke candidly about the necessity of emotional recovery and the process of healing. It's a journey that many entrepreneurs can relate to—the need to step back, reflect, and recalibrate after a fall.Embracing the AI Ecosystem: As Nick reflected on his identity and the role of cryptocurrency in his life, he recognized the need for a shift. His expertise and passion found a new home in the AI ecosystem, a field ripe with challenges that align with his technological prowess.The Dance of Surrender and Manifestation: Our dialogue delved into the delicate balance between surrendering to the unknown and actively shaping one's destiny. Nick emphasized the importance of psychological healing and allowing the subconscious to work its magic before embarking on a new venture.Strategies for Overcoming Adversity: Nick didn't shy away from sharing practical strategies for weathering difficult times. Conducting a thorough post-mortem, seeking honest feedback, and learning from past mistakes are crucial steps. But equally important is the space we give ourselves to heal emotionally and mentally.Looking Ahead with Heart and Resilience: As we discussed his future plans, Nick's enthusiasm for building a company in the AI space was palpable. He remains committed to infusing his work with heart, love, and resilience, tackling the challenges and potential of AI with a thoughtful and ethical approach.The Transformative Power of Resilience: Drawing inspiration from Nick's journey, I reflected on the transformative power of resilience—the ability to turn darkness into light. It's a message of hope and encouragement for all of us to trust in our capacity to navigate life's challenges.A Childhood Lesson in Resilience: Nick shared a poignant story from his childhood, a testament to the resilience that comes from overcoming significant obstacles. It's a powerful reminder that our past experiences can serve as a wellspring of confidence and strength for the future.Embracing Rejection and Redirection: As we wrapped up our conversation, I echoed Nick's sentiments on resilience and empowerment. There's a liberating freedom in setbacks, an opportunity for growth and the discovery of new paths.Thank you so much, Nick Sullivan who was an absolutely amazing guest. Nick never ceases to amaze me in the way that he can look at a problem or his experience from multiple different directions. And one of the things I so loved about our conversation is that he was really able to unpack two seemingly similar circumstances where he felt like the roof got ripped off of the house in terms of the cryptocurrency landscape, and in one of those moments, he decided to stay, and in one of those moments, he decided to go. Or, I think, more akin to his words, he felt forcibly ejected from continuing to do that work.To learn more about Nick visit him on Instagram: @technickai_ Here are some highlights of the episode to look forward to:Heart-Led Leadership (00:02:34): Nick discusses the importance of psychological safety, diversity, love, and empathy in leadership and technology.Healthy Intersection of Humanity and Technology (00:11:14): Nick explores the healthy intersection of humanity and technology, focusing on AI, values, and the need to teach machines love and empathy.Facing Challenges as a CEO (00:19:30): Nick recounts the challenges faced as the CEO of Heart Rhythm, including a crisis and the decision to rebuild the business.The fundraising challenges (00:22:20): Nick discusses the challenges faced in fundraising due to external factors in the cryptocurrency landscape.Reflecting on the closure of Heart Rhythm (00:23:45): Nick reflects on the decision to shut down Heart Rhythm and the perspective shift with time.Reflection on personal journey and trust in the universe (00:27:09): Nick reflects on his personal journey and how his perspective on trusting the universe has shifted over time.Embracing surrender and healing (00:29:41): Nick discusses the tension between surrendering to the unknown and actively guiding his path, as well as the importance of psychological healing.Learning from experience and creating space for healing (00:33:20): Nick shares the importance of conducting a post-mortem and creating space for psychological healing after a challenging experience.Future endeavors in AI space (00:37:30): Nick shares his plans for a new company in the AI space and his focus on building with heart and resilience.Overcoming challenges and embracing resilience (00:40:36): Nick shares how overcoming past challenges has emboldened his confidence and resilience in facing new obstacles. 

This week, Jonathan is joined by Greg Marcus, Endowed Professor of Atrial Fibrillation and Professor of Residence (Medicine) at the University of California, San Francisco, USA, to explore advances in the field of electrophysiology, and how substances such as coffee, alcohol, and cannabis have an effect on cardiac arrythmias, physical activity, and sleep. They further dive into the aims and results of the Health eHeart study, and how technology such as smartwatches can be used in heart disease. Use the following timestamps to navigate the content in this episode: (00:00)-Introduction (04:01)-What inspired Greg to get into medicine, and specifically into cardiology and electrophysiology (06:30)-Electrophysiology 101 (09:10)-Coffee's effects on cardiac arrhythmias (15:31)-Shifts in metabolism triggered by ageing (16:35)-The MARY-JANE Cannabis and Heart Rhythm trial (20:09)-Effects of alcohol on heart outcomes (26:01)-Aims and discoveries of the Health eHeart study

Recognizing the Longstanding Concerns in ECG Interpretation Proficiency Guest: Peter Noseworthy, M.D, M.B.A. Host: Anthony H. Kashou, M.D.  In this episode, we delve deep into the heart of the Mayo Clinic's Heart Rhythm and Physiologic Monitoring Laboratory, exploring its pivotal milestones, innovations, and the collaborative spirit driving its success. Through candid stories of challenges, we gain insight into the lab's resilience and vision for the future of electrocardiography.   Topics Discussed Impact on patient care in diagnosis over time How the lab has adapted to the ever-evolving demands of health care Innovations that have kept the Heart Rhythm and Physiologic Monitoring Laboratory at the forefront Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

A Discussion of Left Bundle Branch Area Pacing Versus Biventricular Pacing as the Initial Implant Strategy for Cardiac Resynchronization Therapy. Danesh Kella, MBBS, FHRS of the Mayo Clinic, Florida hosts a discussion with co-host Jason T. Jacobson, MD, FHRS of Westchester Medical Center and guests Roderick Tung, MD, FHRS of the University of Arizona – Phoenix, and Rajeev Kumar Pathak, MBBS, PhD, FHRS of Australian National University and Canberra Hospital. This episode was recorded live at Heart Rhythm 2023 in New Orleans, Louisiana. https://www.hrsonline.org/education/TheLead Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stock Ownership: Atlas 5D D. Kella: No relevant financial relationships with ineligible companies to disclose. Contributor Disclosure(s): R. Pathak: No relevant financial relationships with ineligible companies to disclose. R. Tung: Honoraria/Speaking/Consulting Fee: Abbott, AtriCure, Biotronik, Boston Scientific, Medtronic

The Young Investigator Award Winners. Danesh Kella, MBBS, FHRS and Jason T. Jacobson, MD, FHRS congratulate the Heart Rhythm 2023 Young Investigator Award winners. This episode was recorded live at Heart Rhythm 2023 in New Orleans, Louisiana. https://www.hrsonline.org/education/TheLead Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stock Ownership: Atlas 5D D. Kella: No relevant financial relationships with ineligible companies to disclose.

A Discussion of Epicardial Roof-Dependent Macro-Reentrant Tachycardia. Jason T. Jacobson, MD, FHRS of Westchester Medical Center – New York Medical College and co-host Danesh Kella, MBBS, FHRS of the Mayo Clinic Jacksonville as they discuss the article Epicardial Roof-Dependent Macro-Reentrant Tachycardia After Ablation of Atrial Fibrillation: Prevalence, Electrophysiological Characteristics, and Ablation Strategy. They are joined by guests Pierre Jais, MD of the Université of Bordeaux, CHU Bordeaux, IHU LIRYC and Apoor Patel, MD of Houston Methodist Hospital. This episode was recorded in front of a live audience at Heart Rhythm 2023 in New Orleans, Lousiana. https://www.hrsonline.org/education/TheLead Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stock Ownership: Atlas 5D D. Kella: No relevant financial relationships with ineligible companies to disclose. Contributor Disclosure(s): P. Jais: Stock Ownership (Privately Held): Farapulse A. Patel: Honoraria/Speaking/Consulting Fee: Biosense Webster, Boston Scientific

A Discussion of Magnetic Resonance Imaging Based Dual Lead Cardiac Resynchronization Therapy. Prashanthan Sanders, MBBS, PhD, FHRS of the University of Adelaide as he discusses Magnetic resonance imaging based Dual lead cardiac Resynchronization therapy: A prospective Left Bundle Branch Pacing Study (MADURAI LBBP study) by Heart Rhythm 2023 Late-Breaking Abstract Author Shunmuga Sundaram Ponnusamy. He is joined by guests Rakesh Gopinathannair, MA, MD, FHRS of the Kansas City Heart Rhythm Institute and Martin K. Stiles, MBChB, PhD, FHRS of Waikato Hospital, Cardiology. This episode of The Lead was recorded in front of live audience at Heart Rhythm 2023 in New Orleans, Lousiana. https://www.hrsonline.org/education/TheLead Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting Fee: Abbott, Boston Scientific, Medtronic; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Becton Dickinson, Boston Scientific, CathRx, EBR Systems, Medtronic, Microport Scientific Corporation, PaceMate   Contributor Disclosure(s): R. Gopinathannair: Honoraria/Speaking/Consulting Fee: Abbott, Boston Scientific, Biosense Webster M. Stiles: Honoraria/Speaking/Consulting Fee: Medtronic, Cyrix Medical, Pfizer, Sanofi

This episode features Dr. David Wang, Co-Director of the Neurovascular Division & Petznick Stroke Center at Barrow Neurological Institute; Dr. Robert Lemery, Cardiac Electrophysiologist at Arizona Heart Rhythm Center; & Dr. Vijay Swarup, Director of Cardiac Electrophysiology at Arizona Heart Rhythm Center & Director of Electrophysiology at St. Joseph's Hospital. Here, they discuss details surrounding their collaborative work with The Arizona Brain and Heart Symposium taking place October 21st & 22nd, 2022. Learn more at https://www.barrowneuro.org/patient-care/support-resources/education-seminars/the-arizona-brain-and-heart-symposium/

Ireland’s Data Protection Commission (DPC) fined Meta over the handling of teenager’s information and GDPR breaches, Fitbit launches Irregular Heart Rhythm Notifications in the EU and Canada, and TikTok reportedly suffered breaches exposing source code and user data. MP3 Please SUBSCRIBE HERE. You can get an ad-free feed of Daily Tech Headlines for $3 aContinue reading "Fitbit launches Irregular Heart Rhythm Notifications in the EU – DTH"